ctDNA Identifies Responders to Radiotherapy and Systemic Treatment in Metastatic Cancer

Text
The European Society for Radiotherapy & Oncology (ESTRO) 2026 conference, set to take place in Stockholm from May 15 to May 19, 2026, will highlight a groundbreaking development in cancer treatment: the use of circulating tumor DNA (ctDNA) to identify patients with metastatic cancer who respond to radiotherapy alongside systemic therapies. This approach, outlined in a report titled Raportul de gardă, represents a critical step toward personalized cancer care, offering clinicians a tool to refine treatment strategies and improve patient outcomes.

Subheading
How ctDNA Enhances Treatment Precision
Circulating tumor DNA, fragments of genetic material shed by tumors into the bloodstream, has emerged as a biomarker for monitoring cancer progression and treatment response. The findings presented at ESTRO 2026 suggest that ctDNA levels can predict which patients with metastatic tumors—such as those with breast, lung, or prostate cancer—benefit most from combining radiotherapy with systemic treatments like chemotherapy or immunotherapy. By analyzing ctDNA before and after radiotherapy, clinicians can gauge whether the therapy is effectively targeting cancer cells, allowing for timely adjustments to the treatment plan.

The study, though not publicly detailed in the available sources, aligns with growing research on liquid biopsies. For instance, a 2023 review in Nature Reviews Clinical Oncology emphasized ctDNA’s potential to detect minimal residual disease and guide therapeutic decisions. The ESTRO 2026 report appears to build on this foundation, focusing specifically on metastatic cases where traditional imaging may not capture early responses.

Subheading
The Role of ESTRO 2026 in Advancing Oncology
As Europe’s largest radiation oncology conference, ESTRO 2026 will bring together over 10,000 experts to discuss innovations in cancer care. The event, hosted at Stockholm’s Mässan exhibition center, will also feature Europe’s largest technical exhibition for medical devices, including advancements in radiation therapy equipment. While the conference’s primary focus is on clinical and technological progress, the ctDNA research underscores a broader shift toward precision medicine.

Siemens Healthineers, a conference sponsor, has highlighted the importance of integrating biomarkers like ctDNA into cancer care workflows. “A holistic approach to cancer treatment requires tools that translate complex data into actionable insights,” said a company spokesperson. “ESTRO 2026 provides a platform to explore how technologies like ctDNA analysis can bridge the gap between research and practice.”

Subheading
Implications for Patient Care
The ability to identify responders to radiotherapy through ctDNA could reduce unnecessary treatments and their associated side effects. For example, patients whose tumors do not respond to radiotherapy might avoid prolonged exposure to radiation, while those who benefit could receive more aggressive or targeted interventions. This aligns with the goals of the European Society for Medical Oncology (ESMO), which advocates for individualized treatment plans based on molecular profiling.

However, challenges remain. ctDNA testing requires standardized protocols for sample collection, analysis, and interpretation. Additionally, while the technology is advancing, its widespread adoption may depend on regulatory approvals and reimbursement policies. The ESTRO 2026 conference is expected to address these hurdles, with sessions dedicated to translating biomarker research into clinical guidelines.

Subheading
What’s Next for ctDNA in Oncology?
The findings from ESTRO 202